Physician profile
Leah Smith
NPI 1841873791
$2,870.04
in general payments reported to CMS, 2019-2025
21 companies · $676 in 2025
The $676 reported for 2025 was more than what 91% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $642 · 2023: $717 · 2024: $620 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $399.27 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $393.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $382.15 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $268.94 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $265.93 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.01 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $166.20 | 2021-2022 | |
| Lilly USA, LLC | $128.68 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.55 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $115.44 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $104.39 | 2022-2025 | Keveyis, Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $61.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $54.32 | 2022-2023 | Quviviq |
| Dexcom, INC. | $47.87 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $46.74 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $46.29 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.81 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $19.84 | 2024 | Verquvo |
| Ardelyx, INC. | $17.47 | 2024 | Ibsrela |
| Amgen INC. | $16.61 | 2024 | Repatha, Otezla |
| Genentech USA, INC. | $6.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.